ACOUSTIC OPTICS FOR MICROSCOPY
Department of Health and Human Services
Agency Tracking Number:
Solicitation Topic Code:
Small Business Information
Neos Technolgies, Inc.
4300-C FORTUNE PL, West Melbourne, FL, 32904
Socially and Economically Disadvantaged:
HO, HUEY C
AbstractDESCRIPTION (Adapted from Applicant's Abstract): This is a Phase I SBIR application to develop an add on system for fluorescence microscopes to provide control over the incident wavelength and to provide accurate spectral analysis and discrimination of spectral bands in image space. This will be accomplished without moving parts at high speed using improved acousto-optic devises. The proposal focuses on the development of transducer technologies such as apodization, array geometries, acousto-optic resonance enhancement and novel fabrication methods involving transducer cutting. The objective is to improve the capabilities of acousto-optic tunable filters by at least an order of magnitude. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 316 --PROJECT NUMBER......1 R43 GM53871-01 INVESTIGATOR NAME/ADDRESS FY 97 GEORGE, JAY IRG/INTRAMURAL UNIT..ZRG7 CODON PHARMACEUTICALS INC AWARD AMOUNT......... $75,000 200 PERRY PARKWAY GAITHERSBURG MD 20877 PERFORMING ORGANIZATION: CODON, INC. TITLE AFFINITY CHROMATOGRAPHY OF NUCLEIC ACIDS ABSTRACT: DESCRIPTION (Adapted from applicant's abstract): This Phase I project aims specifically to demonstrate the feasibility of developing inexpensive reagents to affinity purify recombinant DNA molecules. The methodology, once developed, will be directed to the problem of chromosome purification. During the Phase I period, the applicants will use X chromosome alpha satellite specific sequences to serve as a model for reagent development. Initially, the plan is to test the feasibility of developing reagents to: (1) form triplexes with human chromosome specific centromeric sequences, (2) form triplexes with third strands covalently modified with specific ligands, and (3) to immobilize the specific third strand forming oligonucleotides to solid supports in order to develop affinity purification procedures. Although the overall goal of the project is to develop reagents for chromosome purification, it is expected that after the development of such technology, it could be utilized for the affinity purification of recombinant DNA cloned into plasmids, YACs (yeast artificial chromosomes), phages (lambda and Pl), and cosmids. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 317 --PROJECT NUMBER......2 R44 GM53896-02 INVESTIGATOR NAME/ADDRESS FY 97 MIDDLETON, KIM M IRG/INTRAMURAL UNIT..ZRG3 CYTOSKELETON, INC AWARD AMOUNT......... $349,807 1650 FILLMORE STREET, SUITE 24 DENVER, CO 80206 PERFORMING ORGANIZATION: CYTOSKELETON TITLE DEVELOPMENT OF PRODUCTS TO INVESTIGATE THE CYTOSKELETON ABSTRACT: The eukaryotic cytoskeleton is involved in a diverse number of cellular functions including cell motility, transmembrane signaling and cell shape and division. The role of the cytoskeleton in disease is equally pervasive. Oncogenic transformation, metastatic invasion, neurodegeneration and viral infections are just a few of the disorders that have now been linked to perturbed cytoskeletal function. Over the last decade, interest in this field has spawned the discovery old literally hundreds of novel proteins. Many of them are active areas of basic research and hold great potential as therapeutic drug targets. Clearly these proteins represent an invaluable resource to the scientific community however, in nearly all cases, they are not commercially available. As Cytoskeleton we have recognized the need to introduce these innovative products to academic and industrial researchers. We plan to adapt and improve previously published protein purification protocols in order to meet commercial needs. We arc confident that the availability of highly pure and biologically active proteins will result in enhanced progression towards understanding the mechanisms dictating normal and aberrant cytoskeletal behavior. As well as supplying these reagents, end to develop novel drug screens using stable formulations of our Phase l and Il proteins as potential targets.
* information listed above is at the time of submission.